Directors see significant value @ 3.4c. cheers " The Directors...

Directors see significant value @ 3.4c.

cheers

" The Directors believe that there is significant unrecognised value in the shares of the Company and they intend to exercise some or all of their CDYO Options at the exercise price of 3.4 cents. Cellmid has gone through a period of significant growth since the issuing of the Options. Consumer health sales increased 171% since FY2014 and overall revenue was up 143% during the same period. The Company has built a strong and capable sales and marketing team delivering on its growth strategy. Cellmid’s consumer health subsidiary, Advangen Limited, is ready to capitalise on these assets and roll out its evolis® branded hair loss products in the $3.5 billion USA market in the coming year. The dedicated subsidiaries, Lyramid, Kinera and Advangen, each have a clear therapeutic and commercial focus, hence present targeted investment opportunities for specialist investors. The subsidiaries have their own product development and cost centres improving transparency in preparation for such investment. Investment directly into these subsidiaries will not only enable them to take Cellmid’s midkine assets into the clinic, but also limit dilution to Cellmid shareholders who will benefit from the potential upside. "